Chronic lymphocytic leukemia (CLL) is slow to develop and can be hard to treat as patients relapse or become refractory to currently available therapies. Chimeric antigen receptor T-cell (CAR-T) therapy is a novel type of treatment which is currently being explored for several forms of hematological cancer, with FDA approvals of CAR-T therapies for acute lymphoblastic leukemia and diffuse large B-cell lymphoma already in place. Recent trials, such as the TRANSCEND CLL004 trial, have reported promising data on the effectiveness of CAR-T in treating patients with CLL.
In this podcast, Jordan Gauthier, MD, MSc, from the Fred Hutchinson Cancer Research Center, WA, Tanya Siddiqi, MD, from the City of Hope National Medical Center, CA, and David Porter, MD, from the Abramson Cancer Center, PA, report on the latest results from clinical trials and discuss at what point we can consider the idea of curing CLL with CAR-T therapy.
The post Latest updates on CAR-T therapy for CLL appeared first on VJHemOnc.
